RIYADH, Saudi Arabia--(BUSINESS WIRE)-- Hevolution Foundation, a global non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, announces that it is providing $5 Million in matching funding to Impetus Grants, a non-profit science funding organization focused on longevity research. The Rosenkranz Foundation, founded by Robert Rosenkranz, chairman of Delphi Capital Management, has also pledged $5 Million, for a total contribution of $10 Million.
“Following our matching funding for Impetus Grants last summer, we are pleased to partner with the organization once again,” commented Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation. “We are confident that this program will help advance the boundaries of aging science and pave the way for transformative discoveries.”
The initiative aims to contribute to the acceleration of scientific breakthroughs in the aging research space and to help extend human healthspan. This pledge builds on Hevolution’s $2 Million in matching funds for Impetus Grants, to support 14 research projects, announced in August 2022. A list of recipients is available here.
Information about applying for funding under this new program will be available on the Impetus Grants website starting on August 1, 2023.
About Hevolution Foundation
Founded in the belief that every person has the right to live a longer, healthier life, Hevolution Foundation is a global catalyst, partner, and convener, on a mission to drive efforts to extend healthy human lifespan and understand the processes of aging. With a focus on aging as a treatable process, Hevolution Foundation aims to increase the number of aging-related treatments on the market, compress the timeline of drug development, and increase accessibility to therapeutics that extend healthy lifespan, also known as healthspan. A non-profit organization headquartered in Riyadh, with an annual budget of up to $1 Billion, Hevolution Foundation plans to open hubs in North America and other global locations to support a cutting-edge, global ecosystem of talent to propel aging and geroscience research forward and achieve medical breakthroughs to help humanity live healthier, longer.
Connect with Hevolution Foundation on LinkedIn, Twitter and at Hevolution.com.
About Impetus Grants
Established in 2021, Impetus Grants is dedicated to supporting innovative ideas in the aging space that might otherwise be overlooked by traditional funders. The organization has successfully deployed over $24 million into scientific research projects, including aging-related clinical trials, biomarker research, and the development of novel tools and model organisms related to the aging process.
About Rosenkranz Foundation
The Rosenkranz Foundation was established by Robert Rosenkranz in 1985. Its focus is on public policy research, higher education, arts and sciences. Robert Rosenkranz is Chairman of Delphi Capital Management and the founder of a group of investment and private equity partnerships. From 1987 until 2018 he served as the Chief Executive Officer of Delphi Financial Group, an insurance company with some $20 billion in assets. Delphi grew from one of his acquisitions and increased its value 100-fold under his leadership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725791268/en/
*Source: AETOSWire
Contacts
Media Contact for Hevolution:
media@hevolution.com
Hevolution Foundation announces new contribution to Impetus Grants to advance aging science
Building on Successful Program from 2022, Commits $5 Million in Matching Funding
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
